<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thalidomide has recently been shown to be useful in the treatment of <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> and may also be useful in the treatment of other <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We have identified a new derivative of thalidomide, S-3-[3-amino-phthalimido]-<z:chebi fb="0" ids="5435">glutarimide</z:chebi> (S-3APG) with dual activity against B-cell <z:hpo ids='HP_0002664'>neoplasias</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>S-3APG was able to directly inhibit the proliferation of <z:mp ids='MP_0009440'>myeloma</z:mp> and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell lines in vitro without showing toxicity to <z:mpath ids='MPATH_458'>normal</z:mpath> bone marrow stromal cells or hematopoietic progenitor cells </plain></SENT>
<SENT sid="3" pm="."><plain>In vivo, S-3APG treatment of drug resistant <z:mp ids='MP_0009440'>myeloma</z:mp> cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in mice was able to produce complete and sustained regressions without any observed toxicity </plain></SENT>
<SENT sid="4" pm="."><plain>Additionally, S-3APG induced complete regressions of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, S-3APG inhibited <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> more potently than thalidomide in the murine corneal micropocket model </plain></SENT>
<SENT sid="6" pm="."><plain>We conclude that S-3APG is a powerful anti-<z:mp ids='MP_0009440'>myeloma</z:mp> and anti-B-cell-<z:hpo ids='HP_0002665'>lymphoma</z:hpo> agent that has both antiproliferative and antiangiogenic effects </plain></SENT>
</text></document>